A recent report by Heru Inc. has found that visual field (VF) results from re:Vive, its wearable testing platform, have a strong association to the ZEISS Humphrey Field Analyzer (HFA).
The study compared the HFA to re:Vive by analyzing 47 eyes — including 21 healthy patients and 16 patients with glaucoma and neuro-ophthalmic diseases, according to a news release,
Results showed a strong correlation between both VF mean deviation and threshold values in all participants’ eyes, the company reported.
A second study was also conducted separately, bringing the total number of participants’ eyes to 81, and found similar results.
“Our patented re:Imagine™ threshold algorithm in the re:Vive platform shows a strong correlation with the Humphrey SITA Standard with excellent reproducibility, and a shorter testing time,” said Heru CEO and founder Mohamed Abou Shousha, MD, PhD.
Additional results included re:Vive performing significantly faster than the HFA SITA Standard, with a 15 percent gain in pathologic eyes and an 8 percent gain in healthy eyes, according to the company.
“Unlike legacy technology requiring patients to fixate on a static location for uncomfortable lengths of time, said Heru Chief Marketing Officer John Trefethen, “Heru’s patented ActiveTrack™ real-time gaze tracking confirms the patient’s fixation is always appropriate, improving data quality while keeping the patient engaged and focused throughout the exam.”